Sanofi & 4 other companies will participate in NIP

Sanofi, Korea Vaccine, Boryeong Bio, GC Pharma

Sanofi Pasteur, Korea Vaccine, Boryung Biopharma, and GC Pharma are expected to participate in the free national vaccination (NIP) project for the 2022-2023 season organized by KCDA

Unlike the previous year, Sanofi Pasteur is expected to participate as a new business operator and Ilyang Pharmaceutical is expected to be excluded.

 

As a result of the bidding conducted through the Nara Market of the Public Procurement Service on the 9th, Sanofi Pasteur was selected as the first choice by writing the lowest price of 14,433.

 

The desired quantity is 2.2 million doses.The second ranking is Korea Vaccine, which participated in 16,670 won, and the desired quantity is 1.7 million doses.

 

The third place is Boryung Bio Pharma, which spent 16,887 won, and the desired quantity is 1.8 million degrees.

 

The fourth ranking was GC Pharma, which offered 10,700 won, and the desired quantity was 6 million doses.

 

Ilyang Pharmaceutical has bid 10,700 won, the same as the GC Pharma, but the desired quantity is 1.9 million doses, which is less than the GC Pharma, so it is expected to be pushed back from the priority.

 

In this bid, the bidder until the purchase quantity reaches the lowest price among the bidders at a unit price below the scheduled price shall be the successful bidder.

 

All five companies that participated in the bidding had lower bidding prices than the scheduled price of 10,807 won.

 

The KCDA suggested a total of 10,665,090 doses.

 

Looking at the desired quantity in the order of the lowest price, the three companies will easily be included in the total purchase volume, with 2.2 million doses of Sanofi, 1.7 million doses of Korean vaccine, and 1.8 million doses of Boryeong Biopharma.

 

The combined total number of these companies is 5.7 million.

 

The remaining quantity is about 4.96 million doses, which is expected to be taken by the GC Pharma which wants 6 million doses.

 

Ilyang Pharmaceutical has written the same price as GC Pharma, but if there are more than two bidders of the same price, it will be pushed out of the bidding range because it prioritizes bidders with high bidding volume.

 

However, the final successful bidder is determined according to the qualification for participation in the bid and the results of the qualification examination.

 

However, as these companies have a lot of experience in participating in the free flu vaccination project, it is expected that the successful bidder will be determined according to the results of the ticket gate unless there is an accident.

 

Performance of Sanofi is 22.3 billion won, Korea Vaccine, 18.1 billion won, Boryung Biopharma, 19.2 billion won, and GC Pharma, 53 billion won.

 

Compared to last year, the supply volume is the result of an increase of about 1 million doses of green cross, 400,000 doses of Korean vaccine, and 200,000 doses of Boryung Biopharma.

 

Sanofi, which was absent last year, will be the only foreign pharmaceutical company to participate and be selected as the top priority, and will supply the second largest quantity after GC Pharma.

 

GSK, which supplies Fluarix Tetra PFS, a quadrivalent vaccine aid, will not participate in the NIP business again this time.